Chromic picolinate treatment

• US 5,087,623 A
• Filed: 03/21/1989
• Issued: 02/11/1992
• Est. Priority Date: 05/31/1988
• Status: Expired due to Term

• Current Assignee: Nutrition 21 A California Limited Partnership, Nutrition21 LLC
• Original Assignee: NITRITION 21
• Inventors: Boynton, Herb, Evans, Gary W.
• Primary Examiner(s): Waddell, Frederick E.
• Assistant Examiner(s): Henley, III, Raymond J.
• Application Number:
  US07/326,590
• Time in Patent Office: 1,057 Days
• Field of Search: 514/505, 514/188, 514/866
• US Class Current: 514/188
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol

Abstract

The administration of chromic picolinate, preferably in the form of chromic tripicolinate, as a prophylactic or therapeutic agent for controlling various blood serum parameters. In particular, the administration is for controlling blood serum lipid levels, including the lowering of undesirably high blood serum LDL-cholesterol levels and the raising of blood serum HDL-cholesterol levels. Additionally, the adminstration is for controlling desirable high blood serum glucose levels, this being particularly applicable for the treatment of maturity-onset diabetes. Additionally, chromic picolinate, preferably in the form of chromic tripicolinate, is admistered to facilitate uptake of amino acids by skeletal muscle. Thus chromic picolinate can act as an effective anabolic agent.

Claims

1. A method for reducing hyperglycemia and stabilizing the level of serum glucose in humans comprising the administration of an effective amount of a composition comprising synthetic chromic tripicolinate to a human in need thereof.

2. The method of claim 1 wherein said chromic tripicolinate is in a pharmaceutically acceptable carrier and is orally ingested.

3. The method of claim 1 wherein said chromic tripicolinate is present in a pharmaceutically acceptable carrier in a dose having at least about 50 micrograms of chromium.

4. The method of claim 1 wherein said chromic tripicolinate is present in a pharmaceutically acceptable carrier in a dose having from about 50 to about 500 micrograms of chromium.

5. The method of claim 1, wherein about 200 micrograms chromium as of chromic tripicolinate are administered each day for a plurality of days.

6. The method of claim 1, wherein about 200 micrograms chromium as of chromic tripicolinate are administered each day for at least about 40 days.

7. A method for reducing hyperglycemia and for stabilizing the level of serum glucose in an individual, comprising administering chromic picolinate, which is substantially free of impurities from brewer'"'"'s yeast, in an effective dose having at least 50 micrograms of chromium per day to an individual in need thereof.

8. The method of claim 7 wherein said chromic tripicolinate is in a pharmaceutically acceptable carrier and is orally ingested.